PPARs in Alzheimer's Disease.
Markus P Kummer1, Michael T Heneka
1Department of Neurology, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.
PPAR Research
|July 23, 2008
Summary
Peroxisome proliferator-activated receptors (PPARs) may offer a new therapeutic target for Alzheimer's disease (AD). PPAR activation shows anti-inflammatory and anti-amyloid effects, suggesting benefits for AD treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Peroxisome proliferator-activated receptors (PPARs) are recognized for their peripheral roles but also influence central nervous system (CNS) disorders.
- Neuroinflammation, driven by neurodegeneration and beta-amyloid deposition, is central to Alzheimer's disease (AD) pathogenesis.
Purpose of the Study:
- To investigate the potential therapeutic role of PPARs in Alzheimer's disease.
- To explore the hypothesis that Nonsteroidal anti-inflammatory drugs (NSAIDs) protect against AD partly through PPARgamma activation.
Main Methods:
- Review of evidence supporting the role of PPARs in CNS disorders.
- Analysis of studies using AD-related transgenic cellular and animal models.
- Examination of the effects of PPAR agonists, such as thiazolidinediones.
Main Results:
- PPARs demonstrate anti-inflammatory effects in macrophages and autoimmune disease models.
- Evidence supports the hypothesis that NSAID protection in AD involves PPARgamma.
- PPARgamma stimulation by agonists yields anti-inflammatory, anti-amyloidogenic, and insulin-sensitizing effects.
Conclusions:
- PPARs are a promising therapeutic target for Alzheimer's disease.
- PPAR agonists have shown encouraging results in clinical trials for AD.
- Targeting PPARs could offer a novel strategy for AD treatment.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...